Tobacco and coffee contain bioactive compounds that may reduce Parkinson's disease risk by targeting key pathways such as MAO ...

Follow Boston.com on Instagram (Opens in a New Tab) Follow Boston.com on Twitter (Opens in a New Tab) Like Boston.com on Facebook (Opens in a New Tab) ...

Shore, P. A., Mead, J. A. R., Kuntzman, R. G., Spector, S., and Brodie, B. B., Science, 126, 1063 (1957).

If you’ve been diagnosed with clinical depression, also known as major depressive disorder (MDD), rest assured there are many treatment options available. Some people will experience only one ...

This production improves thrombin generation and clot formation in patients with hemophilia A or B with inhibitors. The approval is supported by data from the multicenter, open-label phase 3 ...

Concizumab-mtci (Alhemo) is approved for hemophilia A or B with inhibitors, offering a subcutaneous alternative to intravenous treatments. The phase 3 explorer7 trial demonstrated an 86% reduction ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce bleeding episodes in patients aged 12 and older. The FDA recently approved ...

State Key Laboratory of Natural and Biomimetic Drugs and Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China State Key Laboratory of ...

The participants were on stable levodopa or monoamine oxidase-B inhibitor monotherapy for more than three months before enrollment. Study participants received prasinezumab or placebo every 4 weeks ...

These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a ...